Hanmi Pharm Co Ltd

CSR Report

Report overview

The report describes Hanmi Pharm's 2021 performance, including consolidated revenue of KRW 1.2032 trillion and consolidated R&D investment of KRW 161.5 billion. It highlights the first Korean approval of Rolontis and Hanmi Pharm's continued leadership in domestic outpatient prescriptions. Environmental disclosures include a company-wide waste recycling rate of 65% and a reported 24.4% reduction in greenhouse-gas emissions intensity versus the previous year. The report also records Hanmi Pharm's 2021 joining of the UN Global Compact and continued expansion of ESG management.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2021
Period: 1 January 2021 – 31 December 2021
Language
Pages
File size

Standards & Assurance

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

GRI level

Assurance

Provider
Level
Standard
Scope
Statement included
Metrics assured

ESG & Materiality

ESG data

Indicators available in this report:

Scope 1 emissions
Scope 2 emissions
Water consumption
Waste
Employees
Women on the board
Women in management

Materiality

Assessment
Basis
Matrix

Build your research dataset.

Original reports, structured indicators and machine-readable Markdown, tailored to your project.

Explore our services